• Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine 
  • Combines Sandoz expertise in launching / commercializing treatments with Pear’s expertise in developing prescription digital therapeutics 
  • Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients

  • Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine 
  • Combines Sandoz expertise in launching / commercializing treatments with Pear’s expertise in developing prescription digital therapeutics 
  • Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients